Display options
Cite
Chen X, Chen Y, Huang HM, et al. SUN2: A potential therapeutic target in cancer. Oncol Lett. 2018;17(2):1401-1408doi: 10.3892/ol.2018.9764.
Chen, X., Chen, Y., Huang, H. M., Li, H. D., Bu, F. T., Pan, X. Y., Yang, Y., Li, W. X., Li, X. F., Huang, C., Meng, X. M., & Li, J. (2019). SUN2: A potential therapeutic target in cancer. Oncology letters, 17(2), 1401-1408. https://doi.org/10.3892/ol.2018.9764
Chen, Xin, et al. "SUN2: A potential therapeutic target in cancer." Oncology letters vol. 17,2 (2019): 1401-1408. doi: https://doi.org/10.3892/ol.2018.9764
Chen X, Chen Y, Huang HM, Li HD, Bu FT, Pan XY, Yang Y, Li WX, Li XF, Huang C, Meng XM, Li J. SUN2: A potential therapeutic target in cancer. Oncol Lett. 2019 Feb;17(2):1401-1408. doi: 10.3892/ol.2018.9764. Epub 2018 Nov 27. PMID: 30675193; PMCID: PMC6341589.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2019 Feb;17(2):1401-1408. doi: 10.3892/ol.2018.9764. Epub 2018 Nov 27.

SUN2: A potential therapeutic target in cancer.

Oncology letters

Xin Chen, Yu Chen, Hui-Min Huang, Hai-Di Li, Fang-Tian Bu, Xue-Yin Pan, Yang Yang, Wan-Xia Li, Xiao-Feng Li, Cheng Huang, Xiao-Ming Meng, Jun Li

Affiliations

  1. School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
  2. The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, Anhui 230032, P.R. China.
  3. Institute for Liver Diseases of Anhui Medical University, Hefei, Anhui 230032, P.R. China.
  4. Department of Pharmacy, Anqing Municipal Hospital, Anqing, Anhui 246003, P.R. China.

PMID: 30675193 PMCID: PMC6341589 DOI: 10.3892/ol.2018.9764

Abstract

The incidence of cancer is increasing at an alarming rate despite recent advances in prevention strategies, diagnostics and therapeutics for various types of cancer. The identification of novel biomarkers to aid in prognosis and treatment for cancer is urgently required. Uncontrolled proliferation and dysregulated apoptosis are characteristics exhibited by cancer cells in the initiation of various types of cancer. Notably, aberrant expression of crucial oncogenes or cancer suppressors is a defining event in cancer occurrence. Research has demonstrated that SAD1/UNC84 domain protein-2 (SUN2) serves a suppressive role in breast cancer, atypical teratoid/rhabdoid tumors and lung cancer progression. Furthermore, SUN2 inhibits cancer cell proliferation, migration and promotes apoptosis. Recent reports have also shown that SUN2 serves prominent roles in resistance to the excessive DNA damage that destabilizes the genome and promotes cancer development, and these functions of SUN2 are critical for evading initiation of cancer. Additionally, increasing evidence has demonstrated that SUN2 is involved in maintaining cell nuclear structure and appears to be a central component for organizing the natural nuclear architecture in cancer cells. The focus of the present review is to provide an overview on the pharmacological functions of SUN2 in cancers. These findings suggest that SUN2 may serve as a promising therapeutic target and novel predictive marker in various types of cancer.

Keywords: DNA damage; SUN2; apoptosis; cancer; proliferation

References

  1. Development. 1999 Jun;126(14):3171-81 - PubMed
  2. Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95 - PubMed
  3. Br J Cancer. 2001 Feb;84(4):512-9 - PubMed
  4. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11943-8 - PubMed
  5. Mol Biol Cell. 2002 Mar;13(3):892-901 - PubMed
  6. J Cell Sci. 2003 Jan 15;116(Pt 2):211-6 - PubMed
  7. Br J Dermatol. 2003 Jan;148(1):102-9 - PubMed
  8. Cell Mol Life Sci. 2003 Sep;60(9):1990-7 - PubMed
  9. Cell Tissue Res. 2004 Feb;315(2):279-83 - PubMed
  10. J Biol Chem. 2004 Jun 11;279(24):25805-12 - PubMed
  11. Curr Med Chem. 2004 Jun;11(12):1629-43 - PubMed
  12. J Clin Oncol. 2005 Jun 10;23(17):3940-7 - PubMed
  13. J Cell Sci. 2005 Aug 1;118(Pt 15):3419-30 - PubMed
  14. Bioessays. 2005 Nov;27(11):1136-46 - PubMed
  15. J Cell Biol. 2006 Jan 2;172(1):41-53 - PubMed
  16. Mol Cell Biol. 2006 May;26(10):3738-51 - PubMed
  17. Nat Rev Mol Cell Biol. 2006 Oct;7(10):782-8 - PubMed
  18. DNA Cell Biol. 2006 Oct;25(10):554-62 - PubMed
  19. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7426-31 - PubMed
  20. Annu Rev Cell Dev Biol. 2007;23:675-99 - PubMed
  21. Mol Cell. 2007 Dec 14;28(5):739-45 - PubMed
  22. Exp Cell Res. 2008 May 1;314(8):1892-905 - PubMed
  23. Cancer Res. 2008 Apr 15;68(8):2773-80 - PubMed
  24. PLoS One. 2008 Aug 20;3(8):e2988 - PubMed
  25. J Exp Clin Cancer Res. 2009 Jan 15;28:8 - PubMed
  26. Nucleic Acids Res. 2009 Apr;37(5):1672-81 - PubMed
  27. Int J Oncol. 2009 Jun;34(6):1653-60 - PubMed
  28. Clin Cancer Res. 2009 Aug 15;15(16):5073-81 - PubMed
  29. J Cell Sci. 2009 Nov 15;122(Pt 22):4099-108 - PubMed
  30. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19017-22 - PubMed
  31. Neuron. 2009 Oct 29;64(2):173-87 - PubMed
  32. Annu Rev Cell Dev Biol. 2010;26:421-44 - PubMed
  33. BMC Cancer. 2010 Jul 12;10:367 - PubMed
  34. Acta Pharmacol Sin. 2010 Sep;31(9):1172-80 - PubMed
  35. Mol Cancer. 2010 Sep 02;9:229 - PubMed
  36. J Gastroenterol Hepatol. 2010 Oct;25(10):1674-80 - PubMed
  37. Mol Cell. 2010 Oct 22;40(2):179-204 - PubMed
  38. J Dermatol Sci. 2011 Mar;61(3):187-93 - PubMed
  39. Acta Pharmacol Sin. 2011 Mar;32(3):375-84 - PubMed
  40. Biochem Biophys Res Commun. 2011 Mar 4;406(1):70-3 - PubMed
  41. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  42. Oncogene. 2012 Feb 16;31(7):858-68 - PubMed
  43. Sci Signal. 2011 Aug 09;4(186):pt5 - PubMed
  44. Oncol Rep. 2012 Mar;27(3):854-60 - PubMed
  45. Biochem Soc Trans. 2011 Dec;39(6):1693-7 - PubMed
  46. J Biol Chem. 2012 Feb 17;287(8):5317-26 - PubMed
  47. Carcinogenesis. 2012 Apr;33(4):751-9 - PubMed
  48. Leuk Res. 1990;14(9):815-21 - PubMed
  49. PLoS One. 2012;7(3):e33608 - PubMed
  50. Med Oncol. 2012 Dec;29(4):2402-8 - PubMed
  51. Hepatology. 2012 Sep;56(3):1025-33 - PubMed
  52. J Transl Med. 2012 Jun 08;10:119 - PubMed
  53. Cell Cycle. 2012 Jul 1;11(13):2495-506 - PubMed
  54. Curr Biol. 2012 Sep 11;22(17):1609-15 - PubMed
  55. Nat Cell Biol. 2012 Dec;14(12):1295-304 - PubMed
  56. Front Pharmacol. 2013 Jan 31;4:5 - PubMed
  57. Oncogene. 2014 Feb 27;33(9):1181-9 - PubMed
  58. Tumour Biol. 2013 Jun;34(3):1847-54 - PubMed
  59. Oncotarget. 2013 Feb;4(2):242-55 - PubMed
  60. PLoS One. 2013;8(3):e60170 - PubMed
  61. J Exp Med. 2013 May 6;210(5):951-68 - PubMed
  62. PLoS One. 2013 Jun 11;8(6):e66502 - PubMed
  63. Med Oncol. 2013 Dec;30(4):700 - PubMed
  64. Br J Cancer. 2013 Nov 12;109(10):2714-23 - PubMed
  65. Am J Cancer Res. 2013 Nov 01;3(5):465-77 - PubMed
  66. FEBS Lett. 2014 Jan 3;588(1):99-104 - PubMed
  67. Curr Mol Med. 2014 Jan;14(1):185-95 - PubMed
  68. World J Gastroenterol. 2013 Dec 28;19(48):9307-17 - PubMed
  69. PLoS Biol. 2014 Jan;12(1):e1001758 - PubMed
  70. J Cancer. 2014 Jan 05;5(2):86-97 - PubMed
  71. PLoS One. 2014 Feb 21;9(2):e89659 - PubMed
  72. Cancer Cell Int. 2014 Mar 07;14(1):24 - PubMed
  73. Carcinogenesis. 2014 Oct;35(10):2164-74 - PubMed
  74. Nat Rev Cancer. 2014 Jun;14(6):406-18 - PubMed
  75. Molecules. 2014 May 30;19(6):7122-37 - PubMed
  76. Cancer Gene Ther. 2014 Jul;21(7):290-6 - PubMed
  77. Gastroenterology. 2014 Oct;147(4):847-859.e11 - PubMed
  78. Int J Nanomedicine. 2014 Jul 03;9:3203-17 - PubMed
  79. Tumour Biol. 2014 Nov;35(11):10699-705 - PubMed
  80. Mol Cancer. 2014 Aug 07;13:184 - PubMed
  81. Mol Cancer. 2014 Aug 07;13:186 - PubMed
  82. Med Oncol. 2014 Sep;31(9):164 - PubMed
  83. FEBS Lett. 2014 Oct 16;588(20):3732-8 - PubMed
  84. Cancer J. 2015 Mar-Apr;21(2):56-61 - PubMed
  85. J Hepatol. 2015 Aug;63(2):408-19 - PubMed
  86. Oncotarget. 2015 Jun 20;6(17):14982-92 - PubMed
  87. PLoS One. 2015 May 08;10(5):e0125779 - PubMed
  88. Oncotarget. 2015 Aug 28;6(25):21004-15 - PubMed
  89. Cancer Med. 2015 Oct;4(10):1547-57 - PubMed
  90. Biomed Res Int. 2015;2015:354517 - PubMed
  91. BMC Med. 2015 Aug 13;13:188 - PubMed
  92. PLoS One. 2015 Aug 18;10(8):e0135704 - PubMed
  93. Sci Rep. 2015 Sep 04;5:13538 - PubMed
  94. Med Sci Monit. 2015 Sep 13;21:2718-25 - PubMed
  95. Clin Cancer Res. 2016 Mar 1;22(5):1222-33 - PubMed
  96. Cancer Biol Ther. 2016;17(1):65-78 - PubMed
  97. Mol Cell. 2015 Nov 19;60(4):661-75 - PubMed
  98. Sci Rep. 2015 Dec 10;5:17940 - PubMed
  99. J Transl Med. 2016 Feb 24;14:56 - PubMed
  100. Free Radic Biol Med. 2016 Nov;100:164-174 - PubMed
  101. Curr Pharm Des. 2016;22(46):6946-6955 - PubMed
  102. Oncotarget. 2017 Jan 24;8(4):6984-6993 - PubMed
  103. Mol Cell Endocrinol. 2017 Aug 15;451:40-52 - PubMed
  104. Front Immunol. 2017 Feb 16;8:56 - PubMed
  105. Tumour Biol. 2017 Apr;39(4):1010428317697576 - PubMed
  106. DNA Repair (Amst). 2017 Jun;54:22-29 - PubMed
  107. Ther Adv Med Oncol. 2017 Apr;9(4):253-267 - PubMed
  108. Cytokine Growth Factor Rev. 2017 Jun;35:27-35 - PubMed
  109. Med Res Rev. 2017 Nov;37(6):1461-1491 - PubMed
  110. Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):211-218 - PubMed
  111. Mutat Res. 2017 Oct;803-805:56-75 - PubMed
  112. J Cell Biol. 1995 May;129(4):1033-47 - PubMed
  113. Am J Pathol. 1993 Jul;143(1):211-20 - PubMed
  114. Nature. 1996 Jan 11;379(6561):183-6 - PubMed

Publication Types